Showing results (1921-1930 of 2,058) with videos related to
Sort By:
Pageof 206
Bioorganic & Medicinal Chemistry Letters|March 11, 2006
Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone leadTheresa M Williams, Craig A Stump, Diem N Nguyen, et al.Bioorganic & Medicinal Chemistry Letters|March 7, 2001
Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferaseC J Dinsmore, J M Bergman, D D Wei, et al.Molecular Psychiatry|August 16, 2017
Precision medicine for suicidality: from universality to subtypes and personalizationA B Niculescu, H Le-Niculescu, D F Levey, et al.Journal of Medicinal Chemistry|June 23, 2007
Discovery of isonicotinamide derived beta-secretase inhibitors: in vivo reduction of beta-amyloidMatthew G Stanton, Shaun R Stauffer, Alison R Gregro, et al.Journal of Medicinal Chemistry|April 11, 2023
1-<i>O</i>-Octadecyl-2-<i>O</i>-benzyl-<i>sn</i>-glyceryl-3-<i>phospho</i>-GS-441524 (V2043). Evaluation of Oral V2043 in a Mouse Model of SARS-CoV-2 Infection and Synthesis and Antiviral Evaluation of Additional Phospholipid Esters with Enhanced Anti-SARS-CoV-2 ActivityAaron F Carlin, James R Beadle, Alex E Clark, et al.JAMA Ophthalmology|September 30, 2018
Myocilin Gene Gln368Ter Variant Penetrance and Association With Glaucoma in Population-Based and Registry-Based StudiesXikun Han, Emmanuelle Souzeau, Jue-Sheng Ong, et al.Annals of Internal Medicine|May 1, 2018
Preventability of Early Versus Late Hospital Readmissions in a National Cohort of General Medicine PatientsKelly L Graham, Andrew D Auerbach, Jeffrey L Schnipper, et al.Mathematical Biosciences|June 3, 2023
Challenges in cybersecurity: Lessons from biological defense systemsEdward Schrom, Ann Kinzig, Stephanie Forrest, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2025
Treatment of Pleural Mesothelioma: ASCO Guideline UpdateHedy L Kindler, Nofisat Ismaila, Lyudmila Bazhenova, et al.The Lancet. Oncology|December 5, 2018
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trialEleftherios P Mamounas, Hanna Bandos, Barry C Lembersky, et al.Pageof 206